TR201910060T4 - SYN3 bileşimleri ve yöntemleri. - Google Patents

SYN3 bileşimleri ve yöntemleri. Download PDF

Info

Publication number
TR201910060T4
TR201910060T4 TR2019/10060T TR201910060T TR201910060T4 TR 201910060 T4 TR201910060 T4 TR 201910060T4 TR 2019/10060 T TR2019/10060 T TR 2019/10060T TR 201910060 T TR201910060 T TR 201910060T TR 201910060 T4 TR201910060 T4 TR 201910060T4
Authority
TR
Turkey
Prior art keywords
syn3
compositions
methods
aqueous
cancer
Prior art date
Application number
TR2019/10060T
Other languages
English (en)
Inventor
M Ihnat Peter
C Witchey-Lakshmanan Leonore
Sandweiss Varda
O Ugwu Sydney
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TR201910060T4 publication Critical patent/TR201910060T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Kanserin tedavisinde yararlı olan ajanları içeren sulu ve susuz çözelti formülasyonları açıklanmaktadır.
TR2019/10060T 2001-12-20 2002-12-20 SYN3 bileşimleri ve yöntemleri. TR201910060T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34232901P 2001-12-20 2001-12-20

Publications (1)

Publication Number Publication Date
TR201910060T4 true TR201910060T4 (tr) 2019-07-22

Family

ID=23341353

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10060T TR201910060T4 (tr) 2001-12-20 2002-12-20 SYN3 bileşimleri ve yöntemleri.

Country Status (13)

Country Link
US (3) US20030170216A1 (tr)
EP (1) EP1456377B1 (tr)
JP (2) JP4727923B2 (tr)
AU (1) AU2002366809A1 (tr)
CA (1) CA2470999C (tr)
CY (1) CY1121982T1 (tr)
DK (1) DK1456377T3 (tr)
ES (1) ES2745068T3 (tr)
MX (1) MXPA04005942A (tr)
PT (1) PT1456377T (tr)
SI (1) SI1456377T1 (tr)
TR (1) TR201910060T4 (tr)
WO (1) WO2003053365A2 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
CN1845932A (zh) * 2003-06-04 2006-10-11 坎基股份有限公司 转染剂
AU2004298991A1 (en) * 2003-12-10 2005-06-30 Canji, Inc Methods and compositions for treatment of interferon-resistant tumors
SI3046536T1 (sl) * 2013-09-19 2019-05-31 Janssen Vaccines & Prevention B.V. Izboljšane formulacije adenovirusa
CA3021073A1 (en) * 2016-04-14 2017-10-19 Trizell Ltd. Viral vector stabilization

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105156B1 (en) 1987-09-17 2006-09-12 The Regents Of The University Of California Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FI106800B (fi) * 1990-12-06 2001-04-12 Hoechst Ag Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
ES2189808T3 (es) 1993-10-15 2003-07-16 Cytrx Corp Composiciones de aporte terapeutico y metodos de uso de las mismas.
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
DE69732029T2 (de) * 1996-04-26 2006-02-23 Merck & Co., Inc. Dna enthaltende impfstoffen
WO1998056422A1 (en) * 1997-06-13 1998-12-17 The University Of Kansas Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
DE19734860C2 (de) * 1997-08-12 1999-12-16 Bosch Gmbh Robert Verfahren zur Bestimmung oxidierbarer Bestandteile in einem Gasgemisch
BR9908754A (pt) * 1998-03-13 2000-11-28 American Home Prod Composições liofilizada e lìquida de polinucleotìdeo e farmacêutica, processos para tratar um paciente mamìfero e para preparar uma composição liofilizada de polinucleotìdeo, produto liofilizado de polinucleotìdeo, e, processo para liofilizar uma composição de polinucleotìdeo
US6166779A (en) * 1999-04-27 2000-12-26 Nucore Technology Inc. Method for analog decimation of image signals
EP1074248A1 (en) * 1999-07-08 2001-02-07 Arnold Hilgers Delivery system for biological material
CA2528136A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
WO2004108898A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CN1845932A (zh) * 2003-06-04 2006-10-11 坎基股份有限公司 转染剂
AU2004298991A1 (en) * 2003-12-10 2005-06-30 Canji, Inc Methods and compositions for treatment of interferon-resistant tumors
JP2008203500A (ja) * 2007-02-20 2008-09-04 Fuji Xerox Co Ltd ホログラム記録材料、ホログラム記録媒体、および、ホログラム記録方法

Also Published As

Publication number Publication date
JP2010095549A (ja) 2010-04-30
AU2002366809A1 (en) 2003-07-09
SI1456377T1 (sl) 2019-09-30
US9115374B2 (en) 2015-08-25
US20150313926A1 (en) 2015-11-05
EP1456377A2 (en) 2004-09-15
AU2002366809A8 (en) 2003-07-09
PT1456377T (pt) 2019-09-10
JP4727923B2 (ja) 2011-07-20
WO2003053365A3 (en) 2003-10-30
CA2470999A1 (en) 2003-07-03
CY1121982T1 (el) 2020-10-14
MXPA04005942A (es) 2005-05-16
EP1456377B1 (en) 2019-06-12
EP1456377A4 (en) 2010-07-07
US20100324126A1 (en) 2010-12-23
CA2470999C (en) 2017-02-21
WO2003053365A2 (en) 2003-07-03
US20030170216A1 (en) 2003-09-11
JP2005513086A (ja) 2005-05-12
DK1456377T3 (da) 2019-09-23
ES2745068T3 (es) 2020-02-27

Similar Documents

Publication Publication Date Title
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
EP1401479A4 (en) DETECTION AND THERAPY OF VULNERABLE PLATES USING PHOTODYNAMIC COMPOUNDS
CY1121982T1 (el) Συνθεσεις syn3 και μεθοδοι
TW200612918A (en) Lonidamine analogs
DK1198233T3 (da) Sulfonamid- og sulfamidsubstituerede imidazoquinoliner
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
TR200100805T2 (tr) Tetrahidropiridoeterler
PL370134A1 (en) Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
TR200103216T2 (tr) Pirimidinon bileşimleri
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
UA85559C2 (en) Aminobenzophenone compounds
DE60334536D1 (de) Furylverbindungen
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE60312211D1 (de) Haarbehandlungsmittel
HK1057336A1 (en) Pharmaceutical solutions of modafinil compounds
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
SE0003476D0 (sv) Compounds
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı